M.S. Biotech grad student at UW Madison, manufacturing tech at Hologic, ultimate frisbee maven, fresh pow aficionado, video editing amateur, and open science supporter.
by Greg Emmerich, UW Madison M.S. Biotechnology Program. Business of Biotechnology: Frontiers and Strategies. Final Paper. April 23rd, 2013. Privacy Disclaimer; Figure Templates. Executive Summary Hologic closed a $3.97 billion deal to acquire Gen-Probe in August 2012. Hologic must be able to create significant value in order to justify such a large purchase as it [&hellip
by Greg Emmerich, UW Madison M.S. Biotechnology Program. Advanced Biotechnology: Global Perspectives. Thesis Paper. April 16th, 2013. Abstract The Digital Revolution has created a knowledge-based society reliant upon a high-tech global economy. The pace of innovation has been exponential, leaving some to wonder what possibilities the future may hold. Big Data is the term given [&hellip
by Greg Emmerich, UW Madison, M.S. Biotechnology Program, Early Drug Discovery Class. December 7th, 2012. Abstract Predictive, preventative and personalized medicine is increasingly becoming a reality with recent advances to whole genome sequencing. Genome wide association studies wield impressive amounts of data, but due to differences in populations tested and analysis methodology, there are very [&hellip
by Greg Emmerich, UW Madison, M.S. in Biotechnology Program, Early Drug Development Class. November 16, 2012 Abstract There is a remarkable moment in science that is best described as the “aha!” moment–the moment when some truth about the universe becomes revealed through precise measurement, observation, and deduction. A seemingly unlikely union between mathematics, physics, and [&hellip